These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38540201)

  • 1. Amelioration of Morphological Pathology in Cardiac, Respiratory, and Skeletal Muscles Following Intraosseous Administration of Human Dystrophin Expressing Chimeric (DEC) Cells in Duchenne Muscular Dystrophy Model.
    Siemionow M; Budzynska K; Zalants K; Langa P; Brodowska S; Siemionow K; Heydemann A
    Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
    Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
    Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model.
    Siemionow M; Brodowska S; Langa P; Zalants K; Kozlowska K; Grau-Kazmierczak W; Heydemann A
    Arch Immunol Ther Exp (Warsz); 2022 Aug; 70(1):20. PubMed ID: 35978142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy.
    Siemionow M; Malik M; Langa P; Cwykiel J; Brodowska S; Heydemann A
    Stem Cell Rev Rep; 2019 Dec; 15(6):827-841. PubMed ID: 31612351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy.
    Siemionow M; Langa P; Harasymczuk M; Cwykiel J; Sielewicz M; Smieszek J; Heydemann A
    Stem Cells Transl Med; 2021 Oct; 10(10):1406-1418. PubMed ID: 34291884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transplantation of Dystrophin Expressing Chimeric Human Cells of Myoblast/Mesenchymal Stem Cell Origin Improves Function in Duchenne Muscular Dystrophy Model.
    Siemionow M; Szilagyi E; Cwykiel J; Domaszewska-Szostek A; Heydemann A; Garcia-Martinez J; Siemionow K
    Stem Cells Dev; 2021 Feb; 30(4):190-202. PubMed ID: 33349121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraosseous transplant of dystrophin expressing chimeric (DEC) cells improves skeletal muscle function in
    Malik M; Siemionow M; Cwykiel J; Heydemann A; Garcia-Martinez J; Siemionow K; Szilagyi E
    Postepy Kardiol Interwencyjnej; 2022 Dec; 18(4):399-406. PubMed ID: 36967847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy.
    Siemionow M; Cwykiel J; Heydemann A; Garcia J; Marchese E; Siemionow K; Szilagyi E
    Stem Cell Rev Rep; 2018 Jun; 14(3):370-384. PubMed ID: 29546607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy.
    Siemionow M; Cwykiel J; Heydemann A; Garcia-Martinez J; Siemionow K; Szilagyi E
    Stem Cell Rev Rep; 2018 Apr; 14(2):189-199. PubMed ID: 29305755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric Cell Therapies as a Novel Approach for Duchenne Muscular Dystrophy (DMD) and Muscle Regeneration.
    Budzynska K; Siemionow M; Stawarz K; Chambily L; Siemionow K
    Biomolecules; 2024 May; 14(5):. PubMed ID: 38785982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric Cell Therapy Transfers Healthy Donor Mitochondria in Duchenne Muscular Dystrophy.
    Siemionow M; Bocian K; Bozyk KT; Ziemiecka A; Siemionow K
    Stem Cell Rev Rep; 2024 Oct; 20(7):1819-1829. PubMed ID: 39017908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The X-linked Becker muscular dystrophy (bmx) mouse models Becker muscular dystrophy via deletion of murine dystrophin exons 45-47.
    Heier CR; McCormack NM; Tully CB; Novak JS; Newell-Stamper BL; Russell AJ; Fiorillo AA
    J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):940-954. PubMed ID: 36628607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up.
    Heydemann A; Bieganski G; Wachowiak J; Czarnota J; Niezgoda A; Siemionow K; Ziemiecka A; Sikorska MH; Bozyk K; Tullius SG; Siemionow M
    Stem Cell Rev Rep; 2023 Jul; 19(5):1340-1359. PubMed ID: 37000376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of Chimeric Cell Therapy in Duchenne Muscular Dystrophy.
    Siemionow M; Ziemiecka A; Bożyk K; Siemionow K
    Biomedicines; 2024 Sep; 12(9):. PubMed ID: 39335509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic-Intraosseous Administration.
    Niezgoda A; Biegański G; Wachowiak J; Czarnota J; Siemionow K; Heydemann A; Ziemiecka A; Sikorska MH; Bożyk K; Siemionow M
    Arch Immunol Ther Exp (Warsz); 2023 Nov; 71(1):24. PubMed ID: 37999748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the
    Potter RA; Griffin DA; Heller KN; Peterson EL; Clark EK; Mendell JR; Rodino-Klapac LR
    Hum Gene Ther; 2021 Apr; 32(7-8):375-389. PubMed ID: 33397205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration.
    Siemionow M; Biegański G; Niezgoda A; Wachowiak J; Czarnota J; Siemionow K; Ziemiecka A; Sikorska MH; Bożyk K; Heydemann A
    Stem Cell Rev Rep; 2023 Nov; 19(8):2724-2740. PubMed ID: 37707670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skeletal muscle fibrosis in the mdx/utrn+/- mouse validates its suitability as a murine model of Duchenne muscular dystrophy.
    Gutpell KM; Hrinivich WT; Hoffman LM
    PLoS One; 2015; 10(1):e0117306. PubMed ID: 25607927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of ultrasonography for non-invasive assessment of diaphragm function in muscular dystrophy.
    Whitehead NP; Bible KL; Kim MJ; Odom GL; Adams ME; Froehner SC
    J Physiol; 2016 Dec; 594(24):7215-7227. PubMed ID: 27570057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased plasma lipid levels exacerbate muscle pathology in the mdx mouse model of Duchenne muscular dystrophy.
    Milad N; White Z; Tehrani AY; Sellers S; Rossi FMV; Bernatchez P
    Skelet Muscle; 2017 Sep; 7(1):19. PubMed ID: 28899419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.